Telehealth company’s planned expansion illustrates how quickly commercial markets are responding to changes in federal oversight of experimental therapies.
Hims & Hers Health plans to begin offering new wellness treatments in November, including an unapproved peptide, as the federal government moves to expand access to certain experimental substances through pharmacy compounding. The announcement, reported by Reuters on November 9, 2026, represents a significant commercial response to a recent policy shift by the Department of Health and Human Services (HHS). It also raises questions about the relationship between regulatory access, manufacturing quality, clinical evidence, and patient safety.
A New Market for Experimental Treatments
The telehealth company expects to introduce treatments involving sermorelin, glutathione, and nicotinamide adenine dinucleotide (NAD+) later this month. It also plans to offer BPC-157 and TB-500, two experimental peptides frequently combined in what consumers call the Wolverine stack, when regulatory conditions permit.
BPC-157 and TB-500 have attracted attention among consumers seeking improved recovery from injuries, reduced inflammation, and tissue repair. However, neither substance is FDA-approved, and adequate clinical evidence establishing their safety and effectiveness for these uses remains lacking.
Hims & Hers CEO Andrew Dudum has indicated that the company intends to manufacture BPC-157 and TB-500 in the United States. The company has invested in domestic peptide manufacturing capabilities and describes its planned offerings as part of a broader effort to provide clinician-supervised access to emerging treatments. The announcement illustrates how quickly established healthcare businesses may respond when federal policy creates new commercial opportunities.
HHS Opens a Regulatory Pathway
On October 30, HHS published notice of an interim enforcement-discretion policy involving six peptide bulk drug substances, including BPC-157 and TB-500. Under specified conditions, HHS does not intend to pursue enforcement action against certain licensed pharmacies and physicians compounding these substances under Section 503A of the Federal Food, Drug, and Cosmetic Act while FDA considers their regulatory status through rulemaking.
The policy follows recommendations made by the FDA’s Pharmacy Compounding Advisory Committee earlier this year and reflects HHS Secretary Robert F. Kennedy Jr.’s stated interest in expanding access to peptides through regulated domestic sources.
Importantly, enforcement discretion is not FDA approval. The policy does not establish that these peptides are safe or effective, nor does it mean compounded preparations have undergone FDA premarket review. The policy is conditional and may be reconsidered if safety signals or product-quality problems emerge.
Hims & Hers has indicated that its introduction of BPC-157 and TB-500 remains dependent on further regulatory developments.
Manufacturing Quality Is Only Part of the Equation
Supporters of expanded peptide compounding argue that regulated domestic production could reduce reliance on unverified overseas suppliers and products marketed for research use. That argument has merit from a manufacturing-quality perspective. Pharmaceutical-grade ingredients, appropriate process controls, product testing, and qualified suppliers can help address concerns involving contamination, impurities, and inconsistent concentrations.
However, manufacturing controls cannot resolve the underlying absence of adequate clinical evidence. For injectable experimental peptides, potential risks extend beyond product purity and sterility to include unknown adverse reactions, uncertain dosing, and insufficient information about long-term effects. The distinction is particularly important as telehealth platforms make these substances more accessible to consumers.
Commercial Expansion and Regulatory Responsibility
Hims & Hers is expanding into peptides while continuing to diversify its healthcare offerings, including weight-management treatments and hormone-related services. The company reported nearly 2.8 million subscribers in its latest quarterly results, illustrating the potential reach of its digital healthcare platform. However, executives indicated that the new peptide offerings are not expected to contribute materially to revenue during the remainder of 2026.
For regulators, the expansion presents a broader challenge: ensuring that commercial availability does not outpace appropriate safeguards for product quality, prescribing, promotional claims, and adverse-event surveillance.
For healthcare providers and consumers, access through an established telehealth company should not be confused with evidence that an experimental treatment provides the advertised benefits.
Access Is Not the Same as Approval
The Hims & Hers announcement marks another development in the rapidly evolving market for experimental peptides. Federal policy may provide new opportunities for regulated manufacturing and pharmacy compounding. Whether those opportunities translate into meaningful therapeutic benefits remains a separate scientific question.
As commercial activity expands, continued scrutiny of clinical evidence, manufacturing practices, regulatory compliance, and patient outcomes will be essential. The central regulatory challenge is not simply whether experimental peptides should be accessible, but how access can be managed without allowing commercial enthusiasm to substitute for demonstrated safety and effectiveness.
When Political Priorities and FDA Science Collide
HHS proposes expanding access to six unapproved peptides despite objections from FDA scientists. This raises questions about regulatory oversight, patient safety, and the distinction between enforcement discretion and drug approval.The Trump administration is moving...
What to Know about FDA’s Revised Peptide Guidance
What Manufacturers Need to Know Seventeen revised draft product-specific guidance documents reflect FDA's evolving scientific and regulatory approach to generic peptide drug development. On July 28, 2026, the U.S. Food and Drug Administration (FDA) published 17...
The Regulatory Dilemma of Experimental Peptides
As demand for experimental peptides grows, a fundamental question confronts federal regulators. Can access to unapproved drug products expand without compromising the standards intended to protect patients? The growing popularity of experimental peptides such as...
FDA Moves Toward New Peptide Compounding Policy
FDA Moves Toward New Peptide Compounding PolicyAgency submits proposed policy change for White House review as HHS signals support for expanded access to experimental peptides Nearly three months after an FDA advisory committee recommended adding six experimental...
